BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saussele S, Haverkamp W, Lang F, Koschmieder S, Kiani A, Jentsch-Ullrich K, Stegelmann F, Pfeifer H, La Rosée P, Goekbuget N, Rieger C, Waller CF, Franke GN, le Coutre P, Kirchmair R, Junghanss C. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol 2020;143:217-31. [PMID: 31590170 DOI: 10.1159/000501927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Faisal Hamdi AI, How SH, Islam MK, Lim JCW, Stanslas J. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant? Expert Review of Anticancer Therapy 2022. [DOI: 10.1080/14737140.2022.2147671] [Reference Citation Analysis]
2 Portakal HS. Molecular Docking Mediated Virtual Drug Screening for GABAA Receptor: Promising Digoxin Derivatives. HJBC 2022. [DOI: 10.15671/hjbc.1139995] [Reference Citation Analysis]
3 Yang J, Surapaneni M, Schiffer CA. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia. Expert Rev Hematol 2022. [PMID: 35544670 DOI: 10.1080/17474086.2022.2077187] [Reference Citation Analysis]
4 Lipton JH, Brümmendorf TH, Gambacorti-passerini C, Garcia-gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. Cancers 2022;14:1805. [DOI: 10.3390/cancers14071805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Madonna R, Pieragostino D, Cufaro MC, Del Boccio P, Pucci A, Mattii L, Doria V, Cadeddu Dessalvi C, Zucchi R, Mercuro G, De Caterina R. Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. J Cell Mol Med 2022. [PMID: 35122387 DOI: 10.1111/jcmm.17008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 El Sharkasy ME, Aboshabana R, Belal F, Walash M, Tolba MM. Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples. Spectrochim Acta A Mol Biomol Spectrosc 2022;264:120235. [PMID: 34371314 DOI: 10.1016/j.saa.2021.120235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mauro MJ. Lifelong TKI therapy: how to manage cardiovascular and other risks. Hematology Am Soc Hematol Educ Program 2021;2021:113-21. [PMID: 34889360 DOI: 10.1182/hematology.2021000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Madonna R, Moscato S, Polizzi E, Pieragostino D, Cufaro MC, Del Boccio P, Bianchi F, De Caterina R, Mattii L. Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. Int J Mol Sci 2021;22:5815. [PMID: 34071707 DOI: 10.3390/ijms22115815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Cheng C, Nguyen MN, Nayernama A, Jones SC, Brave M, Agrawal S, Amiri-Kordestani L, Woronow D. Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature. Vasc Med 2021;26:526-34. [PMID: 33840328 DOI: 10.1177/1358863X211006470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Castagnetti F, Pane F, Rosti G, Saglio G, Breccia M. Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. Front Oncol 2021;11:642005. [PMID: 33796468 DOI: 10.3389/fonc.2021.642005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rea D. Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-71913-5_6] [Reference Citation Analysis]
13 García-Gutiérrez V, Hernández-Boluda JCC. Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. J Clin Med 2020;9:E2251. [PMID: 32679880 DOI: 10.3390/jcm9072251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Russo D, Garcia-Gutierrez JV, Soverini S, Baccarani M. Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. J Clin Med 2020;9:E1709. [PMID: 32498406 DOI: 10.3390/jcm9061709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
15 Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol 2020;316:214-21. [PMID: 32470534 DOI: 10.1016/j.ijcard.2020.05.077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]